Drugs / JTR-161
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04608838 | Jan 2019 → Feb 2021 | ischemic stroke | Teijin Pharma Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-04-18 | Teijin America, Inc. | Results Teijin and JCR Pharmaceuticals Co., Ltd. Cease JTR-161 Dental Pulp Stem Cell Research[Teijin] teijin.com ↗
The primary endpoint was not achieved, however, so the two companies have decided to terminate their agreement and cease joint development And Teijin will return its Japan rights to JCR. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-04-18 | Teijin America, Inc. | Teijin and JCR Pharmaceuticals Co., Ltd. Cease JTR-161 Dental Pulp Stem Cell Research[Teijin] teijin.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JTR-161 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04608838 ↗ |
| Modality | Cell therapy | “It is currently under development as a cell-based therapy for ischaemic stroke.” PMID 35613802 ↗ May 2022 |
| Route | Intravenous | “single intravenous administration within 48 hours of symptom onset” PMID 35613802 ↗ May 2022 |